deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT02340117

Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer

Phase II Study of Combined Targeted p53 Gene Therapy (SGT-53) Plus Gemcitabine/Nab-Paclitaxel for Treatment of Metastatic Pancreatic Cancer

Sponsor: SynerGene Therapeutics, Inc.

Conditions Metastatic Pancreatic Cancer
Interventions Gemcitabine SGT-53 nab-paclitaxel
Updated 13 times since 2017 Last updated: May 28, 2025 Started: Jan 31, 2015 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Metastatic Pancreatic Cancer and is currently ongoing. SynerGene Therapeutics, Inc. leads this study, which shows 13 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2018 · 13 months · monthly snapshot~Jun 2018 – ~Sep 2019 · 15 months · monthly snapshot~Sep 2019 – ~Apr 2020 · 7 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Mar 2022 · 12 months · monthly snapshot~Mar 2022 – ~Mar 2024 · 24 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – present · 13 months · monthly snapshot

Change History

13 versions recorded

  1. Jun 2025 — Present [monthly]

    Active Not Recruiting PHASE2

    Status: Unknown → Active Not Recruiting

  2. Sep 2024 — Jun 2025 [monthly]

    Unknown PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  4. Mar 2024 — Jul 2024 [monthly]

    Unknown Status PHASE2

    Status: Recruiting → Unknown Status

  5. Mar 2022 — Mar 2024 [monthly]

    Recruiting PHASE2

▶ Show 8 earlier versions

  1. Mar 2021 — Mar 2022 [monthly]

    Recruiting PHASE2

  2. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  3. Apr 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  4. Sep 2019 — Apr 2020 [monthly]

    Recruiting PHASE2

  5. Jun 2018 — Sep 2019 [monthly]

    Recruiting PHASE2

  6. May 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  7. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • SynerGene Therapeutics, Inc.
Data source: SynerGene Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations